In 2024 we made significant progress, though we have also faced challenges.
The inception of gMendel® was deeply influenced by our founders’ personal experiences with loved ones affected by genetic conditions. The invaluable time spent with our daughters, sons, siblings, cousins, and close friends has bestowed upon us a profound understanding of the challenges families face and the lengthy process of turning new technologies into practical clinical solutions. Motivated by these encounters, we aim to pioneer affordable and accurate mass screening for early diagnosis in prenatal and newborn care, alleviating the burden on countless families, and significantly reducing healthcare costs.
gMendel® technology is a groundbreaking, AI-powered solution that delivers accurate, fast, and affordable screening for genetic conditions at scale. What sets gMendel® apart is its scalability and focus on mass genetic screening rather than individual diagnostics. Operating on a SaaS model, our platform processes hundreds of thousands of samples, significantly enhancing the speed and efficiency of genetic screening for large populations. This approach not only expedites diagnosis but also democratizes access to genetic insights, enabling large-scale health interventions that are both feasible and financially sustainable. By seamlessly integrating genomics with AI, gMendel® surpasses existing technologies, delivering faster, more affordable, and superior results—all without requiring skilled personnel (i.e. Bioinformaticians for analysis and Geneticists for interpretation).
Experts who have evaluated our technology believe it can drive transformative change. Numerous contracts and LOIs have been signed with health systems, diagnostic laboratories and hospitals. Our excellence has been recognized through grants and the European Commission’s Seal of Excellence, awarded in July 2024.
Thank you for your continued support. We are excited about the journey ahead and fully committed to advancing healthcare innovation across the Global South. Together, we are pioneering affordable and accurate mass screening technologies for early diagnosis in prenatal and newborn care—alleviating the burden on countless families and significantly reducing healthcare costs.
gMendel® Executive Management
Read the full 2024 Year in Review here